Cannabis-Derived Cannabinoids Enhance Silver's Effectiveness Against Drug-Resistant Superbugs

A groundbreaking study published in the Journal of Applied Microbiology has revealed that two lesser-known cannabinoids, cannabichromene (CBC) and cannabigerol (CBG), can dramatically boost the antimicrobial power of silver against some of the most stubborn hospital-acquired infections. The research, led by Dr. Dana Lambert of Andira Pharmaceuticals in collaboration with the University of British Columbia, found that combining these cannabinoids with silver increased its effectiveness by up to 64 times against bacteria such as MRSA, E. coli, and Pseudomonas aeruginosa. This discovery offers a potential lifeline in the ongoing battle against antibiotic-resistant superbugs, an area where major pharmaceutical companies have largely ceased investing due to poor financial incentives

Dr. Lambert’s journey from hospital pharmacist to biotech innovator is rooted in both scientific curiosity and indigenous wisdom. Dissatisfied with the limitations of conventional pharmaceuticals, she left clinical pharmacy in 2013 to pursue a PhD in cannabinoid pharmacology. Her approach was influenced by teachings from indigenous elders, who emphasized the importance of using the whole plant rather than isolated compounds. Lambert recounted, “I asked the cannabis plant (yes, I asked the plant itself, as recommended by the elders) to create better medicine,” underscoring a philosophy that bridges modern science and traditional medicine

The research focused on silver, a time-honored antimicrobial agent that has faced increasing resistance and toxicity issues at higher doses. When paired with CBC and CBG—cannabinoids rarely requested by dispensary customers—the required dose of silver was slashed by up to 64-fold, and the combination was able to rapidly kill bacteria and clear resilient biofilms often found in chronic wounds. Lambert stated, “This work identifies a practical way to revitalize an existing antimicrobial that is already widely used in healthcare.” A particularly striking result was the combination’s sustained effectiveness over a 20-day resistance test, outperforming a standard antibiotic, fusidic acid, which quickly lost potency

The implications of this research are far-reaching given the World Health Organization’s warning that antimicrobial resistance is among the top global health threats. Hospital-acquired infections currently cost the U.S. an estimated $28 to $45 billion annually, and the pharmaceutical industry’s retreat from antibiotic development has left a dangerous void. Now, Andira Pharmaceuticals is preparing for two Phase 1/2a clinical trials of its silver-CBC-CBG topical formulation, branded as Silvanex Topical, targeting surgical wounds and chronic diabetic ulcers. These trials are slated for launch in the fourth quarter of 2026, with FDA Fast Track and QIDP applications planned

Lambert’s unconventional blend of scientific rigor and spiritual openness sets her apart in the pharmaceutical world. “I’m probably the furthest thing from an academic scientist you’ll ever meet,” she admitted, emphasizing her desire to develop effective new drugs by integrating plant intelligence with human ingenuity. For decades, the cannabis industry has focused on THC and, more recently, CBD, largely overlooking CBC and CBG. Yet, as this study demonstrates, these so-called minor cannabinoids may hold major promise for modern medicine

From the OG Lab newsroom perspective, this breakthrough signals a significant shift in how the cannabis industry—and the wider pharmaceutical sector—might approach plant-based therapeutics. As clinical trials progress, the industry will be watching closely to see if these findings can translate into effective treatments for persistent infections. The emergence of CBC and CBG as key players could reshape both the scientific and commercial landscape for medical cannabis worldwide